Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Daratumumab, Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated Efficacy Analysis of CASTOR

Daratumumab is a human CD38 IgGκ monoclonal antibody that demonstrated significant activity and a manageable safety profile in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (RRMM).

Investigators of the CASTOR trial, led by Chanan-Khan, examined subgroups to compare the efficacy of daratumumab added to bortezomib/dexamethasone (DVd) in the bortezomib-naive and bortezomib-experienced patient populations. They also evaluated the efficacy of DVd versus Vd in patients who were refractory to lenalidomide as their last prior line of therapy. Median follow-up was 13.0 months. The following outcomes were observed by subset:

  • Bortezomib-naive patients (n = 172): Median progression-free survival (PFS) was not reached with DVd, and was 7.5 months with Vd. The estimated 12-month PFS was 74.6% versus 32.3%, respectively.
  • Bortezomib-exposed patients (n = 326): Median PFS was 12.4 months with DVd compared with 6.7 months with Vd. Estimated 12-month PFS rates were 51.3% and 15.2%, respectively.
  • Lenalidomide-refractory patients (n = 105): Median PFS was 9.3 months with DVd versus 4.4 months with Vd.

Objective response rates, including rates of very good partial response or better, were significantly improved by DVd in all subsets.

These analyses confirm that the addition of daratumumab to Vd significantly improves outcomes for patients with RRMM, regardless of prior treatment with bortezomib. Importantly, the benefit of DVd versus Vd was maintained in patients who were refractory to lenalidomide as the last prior line of therapy.

Chanan-Khan AA, et al. 2016 ASH. Abstract 3313.

Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018, ONS Conference News
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018, ONS Conference News
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018, ONS Conference News
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018, ONS Conference News
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017